A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Pimavanserin (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 03 Nov 2017 Data presented in an ACADIA Pharmaceuticals Media Release.
- 03 Nov 2017 According to an ACADIA Pharmaceuticals media release, data were presented at the 10th Clinical Trials on Alzheimers Disease (CTAD) meeting.
- 04 Oct 2017 According to an Acadia Pharmaceuticals media release, results from this trial will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History